CD19 and cancer: Leukemia stem cells are CD19-positive malignant lymphoblasts responsible for relapse and resistance to chemotherapy in ALL (121), this fits the principle applied to other malignancies, which states that cancer stem cells are a cellular subpopulation responsible for cancer relapse, dissemination and resistance to conventional therapy due to its high adaptability to external stressors (122–129).